Fig. 3.

CD4⁺IL-17⁺ T lymphocyte population is more potently induced after DCs vaccination in DTH⁺ than in DTH⁻ melanoma patients. PBMC from DTH⁺ and DTH⁻ patients before (untreated) and after (treated) a complete immunotherapy cycle were activated with PMA/Ionomicyne and analyzed by flow cytometry using antibodies against CD4 and IL-17. a Upper panel density plots from one representative analysis of Th17 profile. Lower panel Th17 percentage based on CD4⁺IL-17⁺ T cells in DTH⁺ (untreated and treated, n = 8), and DTH⁻ (untreated and treated, n = 8) patients. b IL-17 ELISA assay in DTH⁻ and DTH⁺ patients’ serum. Statistical analyzes were performed using paired Student’s t-test (*p < 0.05)